About the event
Following valued feedback from our delegates and members, we have taken the decision to flip Real-World Evidence 2022: Rare Diseases and Innovative Therapies into an online-only webinar series event, and therefore will be cancelling the in-person event in London on 29–30 June 2022.
We understand that for many of the community, there is concern around travel and large group events, so we’re excited to be able to bring you the same level of insight and expert discussion online, at your convenience and from the comfort of your home or office. Don’t worry, there’ll still be the opportunity to pose your own questions, and presentations will be available to watch unlimited and on demand.
If you had registered for a place at the in-person event in June, you will have been emailed directly about this – please check your inbox for further information, including on refunds for paid tickets.
Stay tuned for more information on how to access the virtual content (which will launch this summer via The Evidence Base) but if you have any questions in the meantime, please contact us. Further information will be shared on here, as well as via The Evidence Base and email.
The Real-World Evidence Live 2022: Rare Diseases and Innovative Therapies team
Presented by the Journal of Comparative Effectiveness Research and The Evidence Base®, Real-World Evidence: Rare Diseases and Innovative Therapies will unite healthcare stakeholders to discuss and advance agile strategies for accelerating collaboration and patient focus in a post-COVID Europe.
What is Real-World Evidence: Rare Diseases and Innovative Therapies and who is it for?
Do you work in the healthcare industry, and need to learn more about how regulatory agencies and HTAs will work with RWE for rare diseases? Are you a payer trying to understand the implications of high-cost, innovative treatments? Are you a researcher looking to apply RWE in your work? A patient/patient advocate keen to learn more about the potential real-world data offers to rare disease patients? Or are you a consultant, research organisation or service provider looking to connect with RWE and HEOR experts in industry and academia?
RWE – derived from real-world patient data that are routinely collected from a variety of sources (electronic health records, patient surveys, claims databases, digital devices, and many more) – has the potential to completely alter how decisions are made to regulate, grant access to and pay for healthcare. And nowhere is the potential greater than in the research, diagnosis and treatment of rare diseases, where randomized controlled trials are highly challenging, if not impossible, to conduct, and innovative, high-cost and potentially curative therapies have the potential to turn the standard regulatory, access and reimbursement paradigms upside down.
In response to the need to convene all healthcare stakeholders – pharma, biotech & medical device companies, HTAs and regulators, payers, academics, patient advocacy groups and service providers – we have launched Real-World Evidence: Rare Diseases and Innovative Therapies, in partnership with the Journal of Comparative Effectiveness Research and The Evidence Base®. Over the summer of 2022, we’ll virtually convene the RWE community to discuss how we can make the use of RWE in rare diseases and innovative therapies a reality.
The virtual spotlight event will include a mix of pre-recorded expert presentations, as well as live panel discussions and additional content, providing a 360 take on the use of RWE in rare diseases and innovative therapies. All content will be free to access and will be available to watch on demand so you can fit it around your schedule.
What will the virtual spotlight event look like?
This virtual spotlight event will take place over a series of weeks in Summer 2022 and will be hosted on The Evidence Base. It will feature a mix of pre-recorded presentations from industry experts and live panel discussions so you can pose your questions and have your say in the big questions that are facing this field.
All content will be available on-demand, meaning you can access it anywhere at a time that suits you, and will be supplemented with additional digital content including ebooks and interviews with speakers. The programme of content will aim to convene participants working in RWE in rare diseases and innovative therapies, including pharma and biotech, medical device companies, health technology assessors (HTAs), regulators, payers, academics, patient advocacy groups and service providers.
Who will be participating?
- Pharma, biotech & medical device companies
- Academics and researchers in RWE, big data and HEOR
- Patient advocacy groups
- Market access specialists
- Leaders in business insights
- HEOR industry figures
What will be discussed?
Core themes will include:
- Reimbursement and payer models
- Regulatory tools and fairness
- The impact of big data, artificial intelligence and machine learning
- Exploring quality, registries and patient-first practices
Got a question? Contact the RWE 2022 team via [email protected]